Remove Access Remove Chronic Pain Remove Clinical Trials Remove Patients
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

The Centers for Disease Control and Prevention is seeking public comments on how Americans with chronic pain are successfully treating their symptoms. ” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

article thumbnail

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

MMJ Recs

From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52
article thumbnail

UK: David Hardstaff And John Binns Write For Open Access Government Exploring Shifting Sands In The UK CBD Industry

Cannabis Law Report

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52
article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

article thumbnail

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Cannabis Law Report

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. About Silo Pharma. Silo Pharma. For more information, visit www.silopharma.com.